Takashi Morisaki

Dr. Takashi Morisaki


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009
Verified
Journal Article
Closed access
JWJunji Wada
Junji Wada
HSHiroyuki Suzuki
Hiroyuki Suzuki
RFRyouta Fuchino
Ryouta Fuchino
AYAkio Yamasaki
Akio Yamasaki
SNShuntaro Nagai
Shuntaro Nagai
MKMitsuo Katano
Mitsuo Katano

27 May 2004
Verified
Journal Article
Closed access
MKMasayuki Kojima
Masayuki Kojima
TMTakashi Morisaki
Takashi Morisaki
NSNobuhiko Sasaki
Nobuhiko Sasaki
KNKenji Nakano
Kenji Nakano
RMRyuichi Mibu
Ryuichi Mibu
MKMitsuo Katano
Mitsuo Katano

4 July 2020 in Immunological Investigations
Verified
Journal Article
Open access
THTetsuro Hikichi
Tetsuro Hikichi
HOHideya Onishi
Hideya Onishi
TMTakashi Morisaki
Takashi Morisaki
MKMakoto Kubo
Makoto Kubo
THTatsuya Hirano
Tatsuya Hirano
YNYusuke Nakamura
Yusuke Nakamura
Chemorefractory ovarian cancer has limited therapeutic options. Hence, new types of treatment including neoantigen-specific immunotherapy need to be investigated. Neoantigens represent promising targets for personalized cancer immunotherapy. We here describe the clinical and immunological effects of a neoantigen peptide-loaded DC-based immunotherapy in a patient with recurrent and chemoresistant ovarian cancer. A 71-year-old female patient with chemorefractory ovarian cancer and malignant ascites received intranodal vaccination of DCs loaded with four neoantigen peptides that were predicted by our immunogenomic pipeline. Following four rounds of vaccinations with this therapy, CA-125 levels were remarkably declined and tumor cells in the ascites were also decreased. Concordantly, the tumor-related symptoms such as respiratory discomfort improved without any adverse reactions. The reactivity against one HLA-A2402-restricted neoantigen peptide derived from a mutated PPM1 F protein was detected in lymphocytes from peripheral blood by IFN-γ ELISPOT assay. Furthermore, the neoantigen (PPM1 F mutant)-specific TCRs were detected in the tumor-infiltrating T lymphocytes post-vaccination. Our results showed that vaccination with intranodal injection of neoantigen peptide-loaded DCs may have clinical and immunological impacts on cancer treatment.

1 September 2010
Verified
Journal Article
Closed access
JWJunji Wada
Junji Wada
HOHideya Onishi
Hideya Onishi
HSHiroyuki Suzuki
Hiroyuki Suzuki
AYAkio Yamasaki
Akio Yamasaki
SNShuntaro Nagai
Shuntaro Nagai
MKMitsuo Katano
Mitsuo Katano

15 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TMTakashi Morisaki
Takashi Morisaki
TMTakafumi Morisaki
Takafumi Morisaki
MKMakoto Kubo
Makoto Kubo
SMShinji Morisaki
Shinji Morisaki
Yusuke NakamuraYusuke Nakamura
Yusuke Nakamura
HOHideya Onishi
Hideya Onishi
Hundreds of lymph nodes (LNs) are scattered throughout the body. Although each LN is small, it represents a complete immune organ that contains almost all types of immunocompetent and stromal cells functioning as scaffolds. In this review, we highlight the importance of LNs in cancer immunotherapy. First, we review recent reports on structural and functional properties of LNs as sites for antitumor immunity and discuss their therapeutic utility in tumor immunotherapy. Second, we discuss the rationale and background of ultrasound (US)-guided intranodal injection methods. In addition, we review intranodal administration therapy of tumor-specific-antigen-pulsed matured dendritic cells (DCs), including neoantigen-pulsed vaccines.

3 July 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
MKMakoto Kubo
Makoto Kubo
MUMasayo Umebayashi
Masayo Umebayashi
KKKanako Kurata
Kanako Kurata
HMHitomi Mori
Hitomi Mori
MKMasaya Kai
Masaya Kai
TMTakashi Morisaki
Takashi Morisaki
Background/Aim: Epithelial cell adhesion molecule (EpCAM) is expressed in various types of cancer, including breast cancer, and is correlated with metastasis, invasion, therapeutic resistance and prognosis. Moreover, several cell surface markers, such as CD44 and EpCAM, are molecular targets on cancer stem-like cells of breast cancer. The aim of this study was to investigate whether catumaxomab, a clinical-grade bispecific antibody that binds to both EpCAM on tumor cells and CD3 on T-cells, combined with activated T-cells can eliminate chemoresistant triple-negative breast cancer (TNBC) cells in vitro. Materials and Methods: First, a cell line (MUK-BC1) was established from human breast carcinoma cells derived from a patient with chemoresistant and disseminated breast cancer. These EpCAM-positive TNBC cells were almost completely resistant to various drug-mediated cytotoxicities up to a concentration of 10 μg/ml. Results: Pre-treatment with catumaxomab and subsequent addition of interleukin-2/OKT3-activated autologous T-cells eliminated EpCAM-positive TNBC cells. Conclusion: Catumaxomab combined with activated T-cells may be a potent therapeutic modality to overcome chemoresistant EpCAM-positive TNBC cells.